Bromide

Bromide

SCHEMBL3534572

Fc1ccc(C[P+](c2ccccc2)(c2ccccc2)c2ccccc2)cc1Br.[Br-]

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 2/20 0.47
KDM4E B2RXH2 2/20 0.39
FAAH O00519 1/20 0.38
HIF1A Q16665 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
IDO1 P14902 2/20 0.35
TDO2 P48775 1/20 0.35
APP P05067 1/20 0.34
PARP1 P09874 2/20 0.33
PTPN2 P17706 1/20 0.32
PTPN1 P18031 1/20 0.32
ALDH1A1 P00352 1/20 0.31
CYP3A4 P08684 1/20 0.31
KCNH2 Q12809 1/20 0.31
CLPP Q16740 1/20 0.31
KDR P35968 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1346296 0.87 SNCA (0.47) SNCAHIF1ACYP1A2CYP2D6CYP2C19
Bromide SCHEMBL8015170 0.84 SNCA (0.51) SNCAHIF1ACYP1A2CYP2D6CYP2C19
Bromide SCHEMBL30721146 0.84 SNCA (0.51) SNCAHIF1ACYP1A2CYP2D6CYP2C19
Bromide SCHEMBL25411424 0.80 SNCA (0.47) SNCAHIF1AAPP
Bromide SCHEMBL1508663 0.80 SNCA (0.47) SNCAHIF1ACYP1A2CYP2D6CYP2C9
Bromide SCHEMBL5440664 0.78 SNCA (0.45) SNCA
Bromide SCHEMBL1508860 0.77 SNCA (0.47) SNCAHIF1AAPPKCNH2
Bromide SCHEMBL28471353 0.77 SNCA (0.40) SNCAHIF1AALDH1A1
Bromide SCHEMBL8030729 0.75 SNCA (0.50) SNCAHIF1ACYP2D6APPALDH1A1
Bromide SCHEMBL39844 0.75 SNCA (0.73) SNCAHIF1ACYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7700602-B2 Amino-5,5-diphenylimidazolone derivatives for the inhibition of β-secretase WYETH LLC (US) 2010-04-20 US disclosed
EP-1756087-B1 AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE WYETH CORP (US) 2009-10-07 EP disclosed
US-20090093498-A1 AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE WYETH (US) 2009-04-09 US disclosed
US-7482349-B2 Amino-5,5-diphenylimidazolone derivatives for the inhibition of β-secretase WYETH (US) 2009-01-27 US disclosed
EP-1756087-A1 AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE Wyeth (US) 2007-02-28 EP disclosed
WO-2006009653-A1 AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE WYETH (US) 2006-01-26 WO disclosed
US-20050282825-A1 Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase WYETH (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093498-A1 AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE BACE1, BACE2, APP SNCA 472/4885KDM4E 1842/4885FAAH 1285/4885
US-20050282825-A1 Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase BACE1, BACE2, APP SNCA 472/4885KDM4E 1842/4885FAAH 1285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.